PSMA/NKG2DL multispecific CAR T / Celyad Oncology - LARVOL DELTA

Celyad Oncology to Present at the 2024 SITC Annual Meeting (Businesswire) - "Celyad Oncology...today announces two poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held in Houston, November 6-10, 2024."

Clinical data • Genito-urinary Cancer • Oncology • Prostate Cancer

Celyad Oncology Reports First Half Year 2024 Financial Results and Recent Business Highlights (Businesswire) - "Multispecific NKG2D-based CAR T-cell platform...PSMA/NKG2DL tandem CAR T-cells, that encompass the extracellular domain of the natural NKG2D receptor fused to an anti-PSMA CAR to overcome antigen heterogeneity and improve anti-tumor efficacy against prostate cancer were developed and demonstrated functionality in vitro against prostate cancer cell lines expressing or not the tumor-associated antigen PSMA; In vivo proof-of-concept of the company’s CD19/NKG2DL tandem CAR T-cell candidate was also provided in a B-ALL relapse model, showing that this multi-specific CAR T-cell candidate has an enhanced anti-tumor efficacy against heterogeneous lymphoma tumors, or to counteract antigen loss, as compared to currently existing treatment options."

Preclinical • Genito-urinary Cancer • Hematological Malignancies • Lymphoma • Oncology • Prostate Cancer • Solid Tumor